Have multiple conditions? Click here

New Clinical Trials for Gout

The goal of current gout clinical research is to learn more about its causes and related conditions. This will hopefully lead to better gout treatments and ultimately a cure. Although much is known about gout there are ongoing gout clinical trials testing new medications such as anakinra, canakinumab and rilonacept. If you or someone you know has suffered from gout or podagra, please review the list of current gout clinical trials. If you are interested and think you might qualify please contact us. Participation in clinical trials are at no cost to you.
 

What is Gout?

Gout is a condition that occurs when there is painful inflammation of a joint in the body due to elevated levels of uric acid that have crystallized and deposited. In about 50% of the cases of gout the joint affected is the one at the base of the big toe. In this case the ailment is known as “podagra”. Other ways that gout presents itself are as tophi and kidney stones. The cause of gout can usually be linked to diets high in alcohol, meat, sweetened drinks, and seafood. For this reason it gout was historically known as “the disease of kings”. Gout is also a genetic disease.
 

Gout Treatments

Gout treatments initially focus on taking care of the symptoms. Ice can be used to alleviate the pain. A regimen of non-steroid anti-inflammatory drugs or steroids may be given for one to two weeks. If preventative measures are not taken the chances are that the gout will return. Preventative measures for treating gout include eating a low calorie diet, reducing alcohol consumption and taking higher doses of Vitamin C. The goal is to reduce uric acid levels in the body so the gout does not reoccur.

Have multiple conditions? Click here

Showing 1-100 of 123
There are 123 Gout Clinical Trials
Name City State Zip
Gout Clinical Trial Birmingham AL 35216
Gout Clinical Trial Port Orange FL 32129
Gout Clinical Trial DeLand FL 32720
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol Birmingham AL
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Birmingham AL
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol Peoria AZ
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Peoria AZ
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. Mobile AZ 36608
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol Little Rock AR
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Little Rock AR
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. Tustin CA
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol Santa Clara CA 95051
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Santa Clara CA 95051
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. San Diego CA 92103
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. Sacramento CA 95816
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. Pomona CA 91767
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. Burbank CA 91505
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Denver CO
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Newington CT
Apremilast Therapy for Acute Gouty Arthritis Darien CT 06820
An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels. Tampa FL 33612
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. Tampa FL 33614
Safety and Efficacy Study of Intramuscular Uricase-PEG 20 South Miami FL 33143
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. Jupiter FL 33458
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol Celebration FL
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Celebration FL
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. East Point GA 30344
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. Decatur GA 30035
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol Atlanta GA
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels Atlanta GA 30310
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Atlanta GA
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol Honolulu HI
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Honolulu HI
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol Coeur D'Alene ID
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Coeur D'Alene ID
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. Boise ID 83702
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Centralia IL
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol Jeffersonville IN
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Jeffersonville IN
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Bettendorf IA 52722
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. Wichita KA 67208
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. Overland Park KA 66215
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Kansas City KA
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol Louisville KY
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Louisville KY
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. Shreveport LA 71106
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Metairie LA
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. Metairie LA 70006
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. Baton Rouge LA 70808
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. Baton Rouge LA 70809
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Ellsworth ME
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol Chevy Chase MD 20815
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Chevy Chase MD 20815
Assessment of Primary Care Providers' Knowledge and Beliefs Regarding Gout Management Worcester MA 01655
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels Cambridge MA 02138
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol Boston MA
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Boston MA
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. Troy MI 48085
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. Lansing MI 48910
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. Flint MI 48532
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol Detroit MI
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Detroit MI
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. Clarkston MI
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels Rochester MN
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels Minneapolis MN 55455
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol Jackson MS
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Jackson MS
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities St Louis MO
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Great Falls MT 59405
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol Omaha NE
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Omaha NE
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. Omaha NE 68114
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. Omaha NE 68134
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Henderson NV
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities West Orange NJ
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol Albuquerque NM
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Albuquerque NM
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Albany NY
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. Shelby NC 28150
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels Durham NC 27710
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol Charlotte NC
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Charlotte NC
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. 1, Charlotte NC 28209
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Bismarck ND 58501
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol Lima OH
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Lima OH
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. Dayton OH 45417
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. Cincinnati OH 45209
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Ponca City OK
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. Oklahoma City OK 73109
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Medford OR
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol Philadelphia PA
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Philadelphia PA
Safety and Efficacy Study of Intramuscular Uricase-PEG 20 PA 16635
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. PA 16635
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Providence RI
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. Varnville SC 29924
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine. Columbia SC 29204
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral BCX4208 Added to Allopurinol Charleston SC
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Charleston SC

Showing 1-100 of 123
Alabama - Alaska - Arizona - Arkansas - California - Colorado - Connecticut - Delaware - Washington DC - Florida - Georgia - Hawaii - Idaho - Illinois - Indiana - Iowa - Kansas - Kentucky - Louisiana - Maine - Maryland - Massachusetts - Michigan - Minnesota - Mississippi - Missouri - Montana - Nebraska - Nevada - New Hampshire - New Jersey - New Mexico - New York - North Carolina - North Dakota - Ohio - Oklahoma - Oregon - Pennsylvania - Rhode Island - South Carolina - South Dakota - Tennessee - Texas - Utah - Vermont - Virginia - Washington - West Virginia - Wisconsin - Wyoming
For Sponsors: Promote Your Study | For Research Sites: Promote Your Site

Copyright 2012 Clinical Trials Institute, LLC | All Rights Reserved
Login
Forgot password?
Enter your email and we will resend your password
Register